Human papilloma virus (HPV) is one of the most common sexually transmitted infections and cases various cancers in women and men. There are currently three vaccines available, and their efficacy and safely have been thoroughly assessed in females but not males. A new analysis published in the British Journal of Clinical Pharmacology shows that HPV vaccines are safe and well tolerated in the male population, and the side effects that may occur after immunization are similar in both sexes.
The analysis included all reports of adverse events following immunization present in the U.S. Vaccine Adverse Event Reporting System from January 1, 2006 to September 30, 2018.
“To the best of our knowledge, this is one of the first studies focused on the evaluation of the safety profile of HPV vaccines in males,” the authors wrote.
Additional Information
Link to Study: https://onlinelibrary.wiley.com/doi/10.1111/bcp.14584
About the Journal
Published on behalf of the British Pharmacological Society, the British Journal of Clinical Pharmacology features papers and reports on all aspects of drug action in humans: review articles, mini review articles, original papers, commentaries, editorials and letters. The Journal enjoys a wide readership, bridging the gap between the medical profession, clinical research and the pharmaceutical industry. It also publishes research on new methods, new drugs and new approaches to treatment. The Journal is recognised as one of the leading publications in its field. It is online only, publishes open access research through its OnlineOpen programme and is published monthly.
About Wiley
Wiley drives the world forward with research and education. Through publishing, platforms and services, we help students, researchers, universities, and corporations to achieve their goals in an ever-changing world. For more than 200 years, we have delivered consistent performance to all of our stakeholders. The Company's website can be accessed at www.wiley.com.